Tenax Therapeutics, Inc.
TENX
$6.00
-$0.04-0.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.67M | 5.66M | 2.70M | 1.51M | 1.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.79M | 11.34M | 7.29M | 4.62M | 3.67M |
| Operating Income | -11.79M | -11.34M | -7.29M | -4.62M | -3.67M |
| Income Before Tax | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.85M | -10.41M | -6.27M | -3.96M | -3.58M |
| EBIT | -11.79M | -11.34M | -7.29M | -4.62M | -3.67M |
| EBITDA | -- | -- | -7.29M | -4.62M | -3.67M |
| EPS Basic | -2.61 | -0.28 | -0.18 | -0.19 | -1.83 |
| Normalized Basic EPS | -1.63 | -0.18 | -0.11 | -0.12 | -1.14 |
| EPS Diluted | -2.61 | -0.28 | -0.18 | -0.19 | -1.83 |
| Normalized Diluted EPS | -1.63 | -0.18 | -0.11 | -0.12 | -1.14 |
| Average Basic Shares Outstanding | 4.15M | 36.58M | 35.29M | 21.16M | 1.96M |
| Average Diluted Shares Outstanding | 4.15M | 36.58M | 35.29M | 21.16M | 1.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |